## Gregory D Kirk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6142012/publications.pdf Version: 2024-02-01



CRECORY D KIRK

#	Article	IF	CITATIONS
1	Mortality among people who inject drugs: a prospective cohort followed over three decades in Baltimore, MD, USA. Addiction, 2022, 117, 646-655.	3.3	18
2	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. Clinical Infectious Diseases, 2022, 75, 3-10.	5.8	4
3	HIV, psychological resilience, and substance misuse during the COVID-19 pandemic: A multi-cohort study. Drug and Alcohol Dependence, 2022, 231, 109230.	3.2	12
4	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQl21. American Journal of Human Genetics, 2022, 109, 299-310.	6.2	6
5	The relationship of alcohol and other drug use during the COVID-19 pandemic among people with or at risk of HIV; A cross-sectional survey of people enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. Drug and Alcohol Dependence, 2022, 241, 109382.	3.2	4
6	Epigenome-wide association analyses of active injection drug use. Drug and Alcohol Dependence, 2022, 235, 109431.	3.2	5
7	Adverse childhood experiences and comorbidity in a cohort of people who have injected drugs. BMC Public Health, 2022, 22, 986.	2.9	1
8	Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs. Annals of Internal Medicine, 2022, 175, 1083-1091.	3.9	10
9	COVID-19 Vaccine Hesitancy and Vaccination Status in a Community-Based Cohort of People Who Inject Drugs in Baltimore, Maryland, March–June 2021. Public Health Reports, 2022, 137, 1031-1040.	2.5	15
10	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases, 2021, 223, 2090-2098.	4.0	5
11	Rapid Real-time Tracking of Nonpharmaceutical Interventions and Their Association With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity: The Coronavirus Disease 2019 (COVID-19) Pandemic Pulse Study. Clinical Infectious Diseases, 2021, 73, e1822-e1829.	5.8	28
12	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. Journal of Infectious Diseases, 2021, 223, 1905-1913.	4.0	8
13	Human immunodeficiency viral infection and differences in interstitial ventricular fibrosis and left atrial size. European Heart Journal Cardiovascular Imaging, 2021, 22, 888-895.	1.2	15
14	APOL1 variant alleles associate with reduced risk for opportunistic infections in HIV infection. Communications Biology, 2021, 4, 284.	4.4	4
15	The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Baltimore, Maryland. Drug and Alcohol Dependence, 2021, 221, 108584.	3.2	42
16	Incident obstructive lung disease and mortality among people with HIV and a history of injecting drugs. Aids, 2021, 35, 1451-1460.	2.2	3
17	665 Insufficient sleep and mortality among persons who inject drugs (PWID). Sleep, 2021, 44, A260-A260.	1.1	0
18	Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women's perceptions, barriers and preferences. Journal of Virus Eradication, 2021, 7, 100039.	0.5	5

#	Article	lF	CITATIONS
19	HIV is Associated with Impaired Pulmonary Diffusing Capacity Independent of Emphysema. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 64-68.	2.1	5
20	Association of the VACS Index with hospitalization among people with HIV in the NA-ACCORD. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 9-18.	2.1	1
21	Frequency, Risk Factors, and Mediators of Frailty Transitions During Long-Term Follow-Up Among People With HIV and HIV-Negative AGEhIV Cohort Participants. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 110-118.	2.1	11
22	Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV,the, 2021, 8, e690-e700.	4.7	106
23	Trends in fatal and nonfatal overdose by race among people who inject drugs in Baltimore, Maryland from 1998 to 2019. Drug and Alcohol Dependence, 2021, 229, 109152.	3.2	4
24	Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	2
25	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. Journal of Infectious Diseases, 2020, 221, 756-765.	4.0	2
26	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. Infection, Genetics and Evolution, 2020, 77, 104078.	2.3	11
27	Characterizing latent classes of social support among persons who inject drugs. Drug and Alcohol Dependence, 2020, 207, 107816.	3.2	3
28	Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 219-226.	2.1	7
29	The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies. EBioMedicine, 2020, 62, 103102.	6.1	2
30	HLA tapasin independence: broader peptide repertoire and HIV control. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28232-28238.	7.1	51
31	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes and Immunity, 2020, 21, 348-359.	4.1	5
32	Racial differences in α4β7 expression on CD4+ T cells of HIV-negative men and women who inject drugs. PLoS ONE, 2020, 15, e0238234.	2.5	3
33	Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS ONE, 2020, 15, e0230127.	2.5	23
34	Frailty Is Associated With Mortality and Incident Comorbidity Among Middle-Aged Human Immunodeficiency Virus (HIV)–Positive and HIV-Negative Participants. Journal of Infectious Diseases, 2020, 222, 919-928.	4.0	30
35	Identifying the immune interactions underlying HLA class I disease associations. ELife, 2020, 9, .	6.0	17
36	Epigenome-wide association scan identifies methylation sites associated with HIV infection. Epigenomics, 2020, 12, 1917-1927.	2.1	7

#	Article	IF	CITATIONS
37	LB-10. Rapid Assessments of Non-Pharmaceutical Intervention Uptake and Population Mobility Patterns Elucidate SARS-Cov-2 Transmission Dynamics. Open Forum Infectious Diseases, 2020, 7, S848-S848.	0.9	1
38	Recent fentanyl use among people who inject drugs: Results from a rapid assessment in Baltimore, Maryland. International Journal of Drug Policy, 2019, 74, 41-46.	3.3	30
39	Hepatitis B virus perceptions and health seeking behaviors among pregnant women in Uganda: implications for prevention and policy. BMC Health Services Research, 2019, 19, 760.	2.2	13
40	Engagement in treatment for depression among people who inject drugs in Baltimore, Maryland. Journal of Substance Abuse Treatment, 2019, 106, 107-112.	2.8	16
41	Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. Journal of Viral Hepatitis, 2019, 26, 738-749.	2.0	20
42	Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression. Frontiers in Immunology, 2019, 10, 53.	4.8	13
43	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV,the, 2019, 6, e93-e104.	4.7	94
44	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. Nature Immunology, 2019, 20, 824-834.	14.5	87
45	Reducing injection intensity is associated with decreased risk for invasive bacterial infection among high-frequency injection drug users. Harm Reduction Journal, 2019, 16, 38.	3.2	20
46	Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. Addictive Behaviors, 2019, 96, 56-61.	3.0	11
47	Plasma cathelicidin and longitudinal lung function in current and former smokers. PLoS ONE, 2019, 14, e0212628.	2.5	11
48	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	1.3	32
49	Rising role of prescription drugs as a portal to injection drug use and associated mortality in Baltimore, Maryland. PLoS ONE, 2019, 14, e0213357.	2.5	12
50	Durable HIV Suppression Among People Who Inject Drugs From a Community-Based Cohort Study in Baltimore, Maryland, 1997–2017. American Journal of Epidemiology, 2019, 188, 2086-2096.	3.4	6
51	Health insurance coverage is associated with access to substance use treatment among individuals with injection drug use: Evidence from a 12-year prospective study. Journal of Substance Abuse Treatment, 2019, 96, 75-81.	2.8	11
52	Building Leadership Capacity for Mission Execution in a Large Academic Department of Medicine. American Journal of Medicine, 2019, 132, 535-543.	1.5	2
53	Hepatitis E Virus Seroprevalence and Correlates of Anti-HEV IgG Antibodies in the Rakai District, Uganda. Journal of Infectious Diseases, 2018, 217, 785-789.	4.0	20
54	Prescription drug use and misuse in a cohort of people who inject drugs (PWID) in Baltimore. Addictive Behaviors, 2018, 81, 39-45.	3.0	8

#	Article	IF	CITATIONS
55	HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D. Journal of Infectious Diseases, 2018, 217, 413-417.	4.0	8
56	Differential Immunodominance Hierarchy of CD8 <sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	14
57	Correlates of hepatitis B awareness and disease-specific knowledge among pregnant women in Northern and Central Uganda: a cross-sectional study. Hepatology, Medicine and Policy, 2018, 3, 14.	1.7	17
58	Inhibitory killer cell immunoglobulin-like receptors strengthen CD8 <sup>+</sup> T cell–mediated control of HIV-1, HCV, and HTLV-1. Science Immunology, 2018, 3, .	11.9	43
59	Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Scientific Reports, 2018, 8, 7227.	3.3	110
60	Frailty and Cause-Specific Hospitalization Among Persons Aging With HIV Infection and Injection Drug Use. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw142.	3.6	18
61	HIV Infection Is Independently Associated with Increased CT Scan Lung Density. Academic Radiology, 2017, 24, 137-145.	2.5	11
62	Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. Clinical Infectious Diseases, 2017, 65, 235-243.	5.8	15
63	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Scientific Reports, 2017, 7, 15843.	3.3	6
64	Acceptability of a mobile health intervention to enhance HIV care coordination for patients with substance use disorders. Addiction Science & amp; Clinical Practice, 2017, 12, 11.	2.6	55
65	Differential Relationships among Circulating Inflammatory and Immune Activation Biomediators and Impact of Aging and Human Immunodeficiency Virus Infection in a Cohort of Injection Drug Users. Frontiers in Immunology, 2017, 8, 1343.	4.8	9
66	HIV/HCV Co-infection, Liver Disease Progression, and Age-Related IGF-1 Decline. Pathogens and Immunity, 2017, 2, 50.	3.1	4
67	HIV Impairs Lung Epithelial Integrity and Enters the Epithelium to Promote Chronic Lung Inflammation. PLoS ONE, 2016, 11, e0149679.	2.5	55
68	Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Medicine, 2016, 14, 215.	5.5	534
69	Implementation of a COPD Screening Questionnaire in an Outpatient HIV Clinic. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 767-772.	1.6	11
70	Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations. AIDS Research and Human Retroviruses, 2016, 32, 756-762.	1.1	7
71	HIV Suppression Restores the Lung Mucosal CD4 <sup>+</sup> T-Cell Viral Immune Response and Resolves CD8 <sup>+</sup> T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2016, 214, 1520-1530.	4.0	26
72	Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Journal of Infectious Diseases, 2016, 214, 344-352.	4.0	12

#	Article	IF	CITATIONS
73	Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genetics, 2016, 12, e1005921.	3.5	17
74	Provider-Level and Other Health Systems Factors Influencing Engagement in HIV Care: A Qualitative Study of a Vulnerable Population. PLoS ONE, 2016, 11, e0158759.	2.5	23
75	Ecological Momentary Assessment of Illicit Drug Use Compared to Biological and Self-Reported Methods. JMIR MHealth and UHealth, 2016, 4, e27.	3.7	34
76	Lung Density Changes With Growth and Inflation. Chest, 2015, 148, 995-1002.	0.8	20
77	Incarceration and injection drug use in Baltimore, Maryland. Addiction, 2015, 110, 1152-1159.	3.3	41
78	Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs. PLoS ONE, 2015, 10, e0143698.	2.5	8
79	Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1542-1547.	3.6	76
80	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
81	Utilizing mHealth methods to identify patterns of high risk illicit drug use. Drug and Alcohol Dependence, 2015, 151, 250-257.	3.2	12
82	Associations of Circulating Soluble Tumor Necrosis Factor-α Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug Users with or at High Risk for HIV Infection. AIDS Research and Human Retroviruses, 2015, 31, 1257-1264.	1.1	8
83	CD4 <sup>+</sup> T-Cell–Dependent Reduction in Hepatitis C Virus–Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2015, 212, 914-923.	4.0	18
84	Capturing illicit drug use where and when it happens: an ecological momentary assessment of the social, physical and activity environment of using versus craving illicit drugs. Addiction, 2015, 110, 315-325.	3.3	38
85	Uptake and Acceptability of Information and Communication Technology in a Community-Based Cohort of People Who Inject Drugs: Implications for Mobile Health Interventions. JMIR MHealth and UHealth, 2015, 3, e70.	3.7	28
86	Feasibility and Acceptability of Smartphone-Based Ecological Momentary Assessment of Alcohol Use Among African American Men Who Have Sex With Men in Baltimore. JMIR MHealth and UHealth, 2015, 3, e67.	3.7	75
87	A Comparison of Two Measures of HIV Diversity in Multi-Assay Algorithms for HIV Incidence Estimation. PLoS ONE, 2014, 9, e101043.	2.5	16
88	Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology, 2014, 11, 106.	2.0	13
89	Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. Retrovirology, 2014, 11, 122.	2.0	32
90	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. PLoS Genetics, 2014, 10, e1004196.	3.5	83

#	Article	IF	CITATIONS
91	HIV-associated obstructive lung diseases: insights and implications for the clinician. Lancet Respiratory Medicine,the, 2014, 2, 583-592.	10.7	78
92	The association between neighborhood residential rehabilitation and injection drug use in Baltimore, Maryland, 2000–2011. Health and Place, 2014, 28, 142-149.	3.3	9
93	A Cross Sectional Analysis of the Role of the Antimicrobial Peptide Cathelicidin in Lung Function Impairment within the ALIVE Cohort. PLoS ONE, 2014, 9, e95099.	2.5	20
94	Risk Factors for Vitamin D Deficiency among HIV-Infected and Uninfected Injection Drug Users. PLoS ONE, 2014, 9, e95802.	2.5	13
95	"Everything that looks good ain't good!― Perspectives on urban redevelopment among persons with a history of injection drug use in Baltimore, Maryland. International Journal of Drug Policy, 2013, 24, 605-613.	3.3	14
96	Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. Aids, 2013, 27, 2559-2566.	2.2	90
97	Using Mobile Health Technology to Improve HIV Care for Persons Living with HIV and Substance Abuse. AIDS Research and Treatment, 2013, 2013, 1-3.	0.7	22
98	The Exposure Assessment in Current Time Study: Implementation, Feasibility, and Acceptability of Real-Time Data Collection in a Community Cohort of Illicit Drug Users. AIDS Research and Treatment, 2013, 2013, 1-10.	0.7	22
99	HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease. Annals of Internal Medicine, 2013, 158, 658.	3.9	156
100	Performance of a Limiting-Antigen Avidity Enzyme Immunoassay for Cross-Sectional Estimation of HIV Incidence in the United States. PLoS ONE, 2013, 8, e82772.	2.5	57
101	Frailty, HIV Infection, and Mortality in an Aging Cohort of Injection Drug Users. PLoS ONE, 2013, 8, e54910.	2.5	128
102	HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users. Clinical Infectious Diseases, 2011, 53, 1256-1264.	5.8	81
103	HIV Infection in the Etiology of Lung Cancer: Confounding, Causality, and Consequences. Proceedings of the American Thoracic Society, 2011, 8, 326-332.	3.5	50
104	KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection. PLoS Pathogens, 2011, 7, e1002270.	4.7	67
105	Assessment of Liver Fibrosis by Transient Elastography in Persons with Hepatitis C Virus Infection or HIV–Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2009, 48, 963-972.	5.8	134
106	Nonstructured Treatment Interruptions Among Injection Drug Users in Baltimore, MD. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 360-366.	2.1	49
107	Limited Uptake of Hepatitis C Treatment Among Injection Drug Users. Journal of Community Health, 2008, 33, 126-133.	3.8	306
108	HIV Infection Is Associated with an Increased Risk for Lung Cancer, Independent of Smoking. Clinical Infectious Diseases, 2007, 45, 103-110.	5.8	336

#	Article	IF	CITATIONS
109	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	21.4	691
110	Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis, 2006, 27, 2070-2082.	2.8	109